Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Sara Hansard
Proposals to give patients and states more power over health care are “getting some traction,” Sen. Bill Cassidy (R-La.) said July 20.
“I came away very encouraged last night,” after meeting with President Donald Trump over Senate efforts to change the Affordable Care Act, Cassidy said at a forum on the prescription drug delivery system. “The president very much wants a replace with repeal,” Cassidy said, “but he wants something done. And it’s clear that they are willing to do more to achieve something.”
Cassidy made his comments as the Senate grapples with crafting legislation acceptable to both moderates and conservatives after an earlier plan was put on hold. Providing states with block grants to be used for health-care spending, which would allow states to fund health savings accounts for people to buy insurance of their choice, “would be a way to give the power back to the patient, to the state, increasing competition among insurance companies, and getting the federal government out of micro-managing someone’s insurance,” Cassidy said. Cassidy and Sen. Lindsey Graham (R-S.C.) are working on an amendment that would accomplish that, Ty Bofferding, Cassidy’s spokesman, told Bloomberg BNA July 20.
There is bipartisan agreement on trying to find ways to get prescription drug prices down, but until Congress finishes work on legislation to repeal and replace the ACA, “it will be difficult to have a kind of cooperative, formal committee hearing in which we explore” that issue, Cassidy said.
A lack of transparency concerning drug price practices contributes to higher prices, Cassidy said. Until patients have met their health insurance deductibles, they don’t benefit from discounts negotiated through their health insurance policies, but patients typically aren’t aware of the discounts, he said.
“It may be that Congress has to mandate that those patients get point-of-sale rebates,” Cassidy said. When patients pay more than the contracted price, it pushes them more rapidly into the portion of Medicare Part D covered by the government, so not only is the patient paying more than the contractual price, “but the taxpayer’s paying” as well, pushing up Part D costs, he said.
The regulatory system needs to be changed to encourage competition, Food and Drug Administration Commissioner Scott Gottlieb said. “There are places in the pharmaceutical market right now where we’re not seeing the competition that Congress intended,” he said. “That’s what we’re focused on at FDA.”
There are market failures “particularly on the generic drug side,” because companies are taking advantage of some regulations in ways that weren’t intended, or because FDA regulations aren’t working as intended to create competition, Gottlieb said.
He cited instances in which complex drugs “have monopolies in perpetuity largely because we don’t have a good framework for demonstrating sameness,” Gottlieb said. The traditional method for approving generic drugs doesn’t work well in some cases because they can’t be measured easily in blood or they act locally on tissues, he said.
“This is a high priority because this is a whole class of drugs that should be subject to generic competition under the rules that Congress established but aren’t, only because of the complexity of trying to demonstrate sameness for those drugs,” Gottlieb said. Such drugs include metered dose inhalers and some oral drugs, he said.
In other cases, FDA rules are being “gamed in certain ways to forestall generic entry to branded drugs,” Gottlieb said. Branded companies in some cases use risk management plans the FDA puts in place to ensure the safe use of drugs to deny generic drug companies samples they need to do bioequivalent studies to make generic copies, he said.
The FDA is likely to publicly release about 150 letters it has sent to brand-name companies informing them that there is no legal reason for them to deny selling their drugs to generic companies, Gottlieb said. “That will provide public transparency,” he said.
In addition, the FDA may step in to cut off protracted negotiations between brand-name companies and generic companies over risk management plans that must be used, which would “allow the generic companies to go their own way on their own separate REMS [risk evaluation and mitigation strategy],” Gottlieb said.
Probably the biggest impediment to competition are some contracts brand-name companies have with distributors, Gottlieb said. They include language that prevents the intermediaries from selling to generic drug companies. “That again makes it hard for the generic companies to get access to the physical samples they need to do the bioequivalent studies,” he said. This is an area “where we can do something on the FDA side.”
The FDA is publishing a list of drugs with few generic competitors, and the agency is on track to eliminate its backlog of drug applications by the end of 2018, Gottlieb said.
To contact the reporter on this story: Sara Hansard in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Kendra Casey Plank at email@example.com
Information on the Prescription Drug Delivery System: Tackling Costs, Ensuring Access is at http://src.bna.com/qYt.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)